Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Total Non-Current Liabilities (2017 - 2025)

Pharma-Bio Serv's Total Non-Current Liabilities history spans 9 years, with the latest figure at $1.7 million for Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities changed N/A year-over-year to $1.7 million; the TTM value through Jul 2025 reached $1.7 million, changed N/A, while the annual FY2024 figure was $1.9 million, N/A changed from the prior year.
  • Total Non-Current Liabilities reached $1.7 million in Q3 2025 per PBSV's latest filing, down from $1.8 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $8.9 million in Q1 2021 to a low of $1.7 million in Q3 2025.
  • Average Total Non-Current Liabilities over 5 years is $3.9 million, with a median of $4.2 million recorded in 2022.
  • Peak YoY movement for Total Non-Current Liabilities: soared 77.42% in 2021, then crashed 50.81% in 2022.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $5.0 million in 2021, then plummeted by 50.81% to $2.5 million in 2022, then rose by 9.34% to $2.7 million in 2023, then dropped by 28.6% to $1.9 million in 2024, then fell by 13.42% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for PBSV's Total Non-Current Liabilities are $1.7 million (Q3 2025), $1.8 million (Q2 2025), and $1.9 million (Q4 2024).